Alphabet Inc. Reduces Holdings in Maze Therapeutics, Inc. $MAZE

Alphabet Inc. trimmed its stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) by 42.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,388,583 shares of the company’s stock after selling 1,023,888 shares during the quarter. Maze Therapeutics comprises 2.2% of Alphabet Inc.’s holdings, making the stock its 10th biggest position. Alphabet Inc.’s holdings in Maze Therapeutics were worth $57,529,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics during the 4th quarter worth about $39,000. Ameritas Investment Partners Inc. raised its position in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after buying an additional 1,725 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Maze Therapeutics during the 3rd quarter worth about $52,000. Finally, Legal & General Group Plc raised its position in shares of Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after buying an additional 3,371 shares in the last quarter.

Insider Activity

In other news, insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total transaction of $190,275.00. Following the sale, the insider owned 10,503 shares in the company, valued at $266,461.11. The trade was a 41.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 25,582 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $26.02, for a total transaction of $665,643.64. Following the sale, the chief executive officer owned 350,987 shares in the company, valued at $9,132,681.74. This represents a 6.79% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 89,502 shares of company stock worth $2,733,139 over the last three months. 5.30% of the stock is owned by insiders.

Maze Therapeutics Stock Down 0.2%

NASDAQ MAZE opened at $24.05 on Friday. Maze Therapeutics, Inc. has a 12 month low of $9.83 and a 12 month high of $53.65. The company’s 50 day simple moving average is $26.10 and its 200 day simple moving average is $36.88. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. The company has a market capitalization of $1.33 billion, a P/E ratio of -9.51 and a beta of 2.26.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. Equities research analysts expect that Maze Therapeutics, Inc. will post -2.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on MAZE. Truist Financial dropped their price target on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, April 14th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Guggenheim boosted their target price on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. HC Wainwright boosted their target price on shares of Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, March 31st. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Maze Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.